Literature DB >> 25100807

Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran.

Bethany Weiler1, Ellen T Marciniak1, Robert M Reed1, Michael T McCurdy1.   

Abstract

Novel anticoagulants are increasingly utilised in lieu of warfarin to treat non-valvular atrial fibrillation. Their clinical use in other non-FDA approved settings is also increasing. We present a case in which a patient abruptly stopped taking dabigatran due to a small bowel obstruction and shortly thereafter suffered a myocardial infarction complicated by left ventricular thrombosis with fatal embolisation to the superior mesenteric artery. In this context, we discuss the possibility of a rebound phenomenon of hypercoagulability with abrupt cessation of novel anticoagulants. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25100807      PMCID: PMC4091470          DOI: 10.1136/bcr-2014-203910

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Left ventricular thrombus in acute myocardial infarction.

Authors:  J M van Dantzig; B J Delemarre; H Bot; C A Visser
Journal:  Eur Heart J       Date:  1996-11       Impact factor: 29.983

2.  Thrombus in the left ventricle of a child with systemic emboli: an unusual presentation of hereditary protein C deficiency.

Authors:  A Matitiau; E Tabachnik; D Sthoeger; E Birk
Journal:  Pediatrics       Date:  2001-02       Impact factor: 7.124

3.  A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).

Authors:  Frans Van de Werf; Martina Brueckmann; Stuart J Connolly; Jeffrey Friedman; Christopher B Granger; Sebastian Härtter; Ruth Harper; Arie Pieter Kappetein; Thorsten Lehr; Michael J Mack; Herbert Noack; John W Eikelboom
Journal:  Am Heart J       Date:  2012-06       Impact factor: 4.749

Review 4.  Review of the rebound phenomenon in new anticoagulant treatments.

Authors:  Cedric Hermans; Donald Claeys
Journal:  Curr Med Res Opin       Date:  2006-03       Impact factor: 2.580

Review 5.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

Authors:  Ken Uchino; Adrian V Hernandez
Journal:  Arch Intern Med       Date:  2012-01-09

6.  Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus.

Authors:  W H Leung; K L Wong; C P Lau; C K Wong; H W Liu
Journal:  Am J Med       Date:  1990-10       Impact factor: 4.965

7.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Sebastian Schellong; Henry Eriksson; David Baanstra; Anne Mathilde Kvamme; Jeffrey Friedman; Patrick Mismetti; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

8.  Left ventricular thrombus sans overt cardiac pathology.

Authors:  Om P Yadava; Sumit Yadav; Saurabh Juneja; Vijay K Chopra; Rajeev Passey; Rajen Ghadiok
Journal:  Ann Thorac Surg       Date:  2003-08       Impact factor: 4.330

9.  Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.

Authors:  E Perzborn; S Heitmeier; U Buetehorn; V Laux
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

Review 10.  Left ventricular thrombus formation after acute myocardial infarction.

Authors:  Ronak Delewi; Felix Zijlstra; Jan J Piek
Journal:  Heart       Date:  2012-12       Impact factor: 5.994

View more
  1 in total

1.  Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.

Authors:  Nina Vene; Alenka Mavri; Mirjam Gubenšek; Gregor Tratar; Tjaša Vižintin Cuderman; Maja Pohar Perme; Aleš Blinc
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.